Mounjaro is a self-administered, once-weekly subcutaneous injection
Semaglutide may not be recommended for individuals with: Type 1 diabetes Semaglutide enhances insulin secretion in response to food, which is ineffective in type 1 diabetes as the body cannot produce insulin
GLP-1 also helps manage blood sugar in people with type 2 diabetes, and individuals that are overweight or obese
Whilst no specific contraindication exists for using both together, this combination requires careful consideration of potential benefits, risks, and individual suitability
New data tie GLP-1 therapies to GERD by Jennifer Ford "These potential risks should be weighed against the established clinical benefits of this drug class." Its not the polyp, its the provider: Study by Julian Upton High-risk polyps are usually considered the main reason for shortened surveillance intervals
Thats why its so important to work with a provider who is familiar with the diagnosis and treatment of overt versus subclinical hypothyroidism
